Abiopharma

New Form 6-K - Haleon plc Filed: 2025-08-05 AccNo: 0001654954-25-008968 Size: 39 KB

Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115

New Form 8-K - CURIS INC Filed: 2025-08-05 AccNo: 0001108205-25-000079 Size: 263 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

New Form 8-K - MEI Pharma, Inc. Filed: 2025-08-05 AccNo: 0000950170-25-102419 Size: 177 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Butterfly Network, Inc. - Butterfly Network Advances AI-Powered Aortic Valve and Aorta Screening with New Research and Training Tools

New Form 8-K - SenesTech, Inc. Filed: 2025-08-05 AccNo: 0001213900-25-071743 Size: 594 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Imunon, Inc. Filed: 2025-08-05 AccNo: 0001493152-25-011597 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Curis Provides Second Quarter 2025 Business Update

SenesTech Announces Warrant Exercise for $6.3 Million in Gross Proceeds

Tharimmune Inc Notification (THAR)

New Form 8-K - CORE MOLDING TECHNOLOGIES INC Filed: 2025-08-05 AccNo: 0001026655-25-000066 Size: 486 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

electroCore Appoints James C. Theofilos to the Board of Directors

CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer